AstraZeneca Oncology Updates Prompt Fresh Look At Valuation And Growth Potential [Yahoo! Finance]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Yahoo! Finance
Health Canada has approved AstraZeneca's Koselugo for adults with neurofibromatosis type 1 and inoperable plexiform neurofibromas. The US FDA has granted Priority Review to the supplemental application for ENHERTU in early stage HER2 positive breast cancer, filed by AstraZeneca and Daiichi Sankyo. For investors watching AstraZeneca (LSE:AZN), these updates are closely aligned with its rare disease and oncology focus. Koselugo's approval in Canada adds an option where treatment choices for adult NF1 patients are limited, while ENHERTU continues to be positioned within HER2 targeted breast cancer care. Together, they broaden the company's presence across specialized, high medical need segments. Investors may monitor how quickly Koselugo is adopted in the Canadian market and how the FDA's Priority Review for ENHERTU progresses. Any regulatory outcomes and subsequent label changes can influence how these medicines fit into treatment guidelines and may shape expectations around Astr
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Is Now The Right Time To Reassess Daiichi Sankyo (TSE:4568) After Recent Share Price Weakness? [Yahoo! Finance]Yahoo! Finance
- Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms [Yahoo! Finance]Yahoo! Finance
- Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs [Yahoo! Finance]Yahoo! Finance
- Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp [Yahoo! Finance]Yahoo! Finance
- Allegro's osteoarthritis hydrogel resolves lameness in animal study [Yahoo! Finance]Yahoo! Finance